Figure 4 of Jiang, Mol Vis 2012; 18:2096-2106.

Figure 4. B cell lymphoma (Bcl)-2 and Bcl-XL mRNA expression after treatment of p38 mitogen-activated protein kinases (MAPK) inhibitor and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) siRNA. SB203580 and NF-κB siRNA inhibited Bcl-2 and Bcl-XL mRNA expression at 8 h after ischemia/reperfusion (I/R). *Statistically significant compared to the I/R control: p<0.05. n=6 in each group. Bcl-2 and Bcl-XL mRNA expressions were given as mean±standard deviation (SD)